TGFB1 and neoplasm: One of six (16.67%) mice from the anti-PD-L1 group and three of six (50%) mice from the anti-PD-L1 plus anti-TGF-β group had a complete response and were re-challenged with Hu-PD-L1 MC38 cells, implanted s.c. on the opposite flank from the original tumor.